Global GERD Market 2016-2020

  • ID: 3608996
  • Report
  • Region: Global
  • 84 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Ahn-Gook Pharmaceutical
  • Cancer Advances
  • Daewoong Pharmaceutical
  • GlaxoSmithKline
  • Johnson & Johnson
  • SFJ Pharmaceuticals Group
  • MORE
About GERD Drugs

Gastroesophageal reflux disease (GERD) is a chronic digestive disorder that affects the lower esophageal sphincter (LES), the ring of muscle between the stomach and esophagus. It occurs when acidic stomach juices, or food and fluids flow back up into the food pipe (esophagus). The backwash irritates the lining of the esophagus and causes GERD. It affects all ages from infants to older adults. The symptoms of GERD include difficulty while swallowing (dysphagia), heartburn sensation, regurgitation or acid reflux, dry cough, sore throat, and chest pain.

GERD is believed to be caused by the overuse of certain medications, such as calcium channel blockers, nitrates and antihistamines. Unhealthy lifestyle factors such as smoking, drinking, slouching, consuming caffeinated drinks, eating large meals, and sleeping immediately after eating are some other typical causes for the occurrence of GERD. Pharmaceutical agents that are used to prevent complications and reduce morbidity in patients with GERD include antacids, H2 receptor antagonists, proton pump inhibitors (PPIs), and prokinetic agents.

The analysts forecast the global GERD drugs market to grow at a CAGR of 2.85% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global GERD drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of various drug classes used in the treatment of GERD.

The market is divided into the following segments based on geography:
- Americas
- APAC
- Europe

The report, Global GERD Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- AstraZeneca
- Eisai
- GlaxoSmithKline
- Johnson & Johnson
- Takeda

Other prominent vendors
- Ahn-Gook Pharmaceutical
- Cancer Advances
- CJ Cheil Jedang
- Daewoong Pharmaceutical
- Ironwood Pharmaceuticals
- RaQualia Pharma
- SFJ Pharmaceuticals Group
- Sucampo Pharmaceuticals
- Vecta Pharmaceuticals
- Wockhardt
- Yuhan
- Zeria Pharmaceutical

Market drivers
- Unmet medical needs
- For a full, detailed list, view the full report

Market challenges
- Increased preference for CAM
- For a full, detailed list, view the full report

Market trends
- Increase in awareness about GERD
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Ahn-Gook Pharmaceutical
  • Cancer Advances
  • Daewoong Pharmaceutical
  • GlaxoSmithKline
  • Johnson & Johnson
  • SFJ Pharmaceuticals Group
  • MORE
PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market overview
  • Top-vendor offerings
  • Product profiles
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
PART 05: Disease overview
  • Understanding the disease
  • Types of GERD
  • Signs and symptoms
  • Risk factors
  • Diagnosis
  • Treatment
  • Usage of OTC drugs in GERD
  • Epidemiology
  • Economic burden
PART 06: Pipeline portfolio
  • Information on pipeline candidates
PART 07: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 08: Market segmentation by drug class

PART 09: Global antacids market
  • Introduction
  • Market overview
PART 10: Global PPI drugs market
  • Introduction
  • Market overview
PART 11: Global H2 receptor antagonist drugs market
  • Introduction
  • Market overview
PART 12: Market segmentation by route of administration38
  • Oral
  • Parenteral
PART 13: Market segmentation by dosage form
  • Solid
  • Liquid
PART 14: Geographical segmentation
  • Global GERD drugs market segmentation by geography
  • GERD drugs market in the Americas
  • GERD drugs market in EMEA
  • GERD drugs market in APAC
PART 15: Market drivers
  • Lifestyle factors
  • Overuse of medicines and dietary supplements
  • Unmet medical needs
  • Increase in prevalence of GERD
  • Cost-effective OTC drugs
PART 16: Impact of drivers

PART 17: Market challenges
  • Increased preference for CAM
  • Adverse effects of drugs
  • Generic erosion
  • Counterfeit drugs
PART 18: Impact of drivers and challenges

PART 19: Market trends
  • Self-medication
  • Increase in awareness about GERD
  • Intense competition
  • Strategic alliances
PART 20: Vendor landscape
  • Competitive scenario
PART 21: Key vendor analysis
  • AstraZeneca
  • Eisai
  • GSK
  • Johnson & Johnson
  • Takeda
  • Other prominent vendors
PART 22: Appendix
  • List of abbreviations
PART 23: About the Author

Exhibit 01: Product offerings
Exhibit 02: Symptoms of pediatric GERD
Exhibit 03: GERD symptoms of older children and adolescents
Exhibit 04: Common risk factors for GERD
Exhibit 05: Dose, frequency, and average generic prices
Exhibit 06: Alternative treatment for GERD
Exhibit 07: Time line of the US FDA approved drugs for the treatment of GERD
Exhibit 08: Comparison between prescription and OTC drugs
Exhibit 09: Advantages and disadvantages of OTC drugs
Exhibit 10: Pipeline molecules for GERD
Exhibit 11: GERD clinical trials by development phase
Exhibit 12: GERD clinical trials by trial status
Exhibit 13: Global GERD drugs market 2015-2020 ($ billions)
Exhibit 14: Five forces analysis
Exhibit 15: Global GERD drugs market segmentation by drug class
Exhibit 16: Global GERD drugs market segmentation by drug class 2015
Exhibit 17: Global antacids market 2015-2020 ($ billions)
Exhibit 18: PPI sales in major non-US markets 2013 ($ millions)
Exhibit 19: Global PPIs market 2015-2020 ($ billions)
Exhibit 20: Global H2 receptor antagonists market 2015-2020 ($ billions)
Exhibit 21: Global GERD drugs market segmentation by route of administration
Exhibit 22: Global GERD drugs market segmentation by dosage form
Exhibit 23: Global GERD drugs market by geography 2015
Exhibit 24: Global GERD drugs market by geography 2015-2020 ($ billions)
Exhibit 25: GERD drugs market in the Americas 2015-2020 ($ billions)
Exhibit 26: GERD drugs market in EMEA 2015-2020 ($ billions)
Exhibit 27: GERD drugs market in APAC 2015-2020 ($ billions)
Exhibit 28: Impact of drivers
Exhibit 29: Common side effects associated with Nexium, Prontonix, Aciphex, and other heartburn medications
Exhibit 30: Impact of drivers and challenges
Exhibit 31: Drugs that underwent Rx-to-OTC switch in the US
Exhibit 32: AstraZeneca: Business segmentation by revenue 2014
Exhibit 33: AstraZeneca: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 34: AstraZeneca: Geographical segmentation by revenue 2014
Exhibit 35: AstraZeneca: YoY revenue growth of Nexium 2012-2014 ($ billions)
Exhibit 36: AstraZeneca: YoY revenue growth of Losec 2012-2014 ($ millions)
Exhibit 37: AstraZeneca: YoY revenue growth of Vimovo 2012-2014 ($ millions)
Exhibit 38: AstraZeneca: Key takeaways
Exhibit 39: Eisai: Business segmentation by revenue 2014
Exhibit 40: Eisai: Business segmentation by revenue 2013 and 2014 ($ millions)
Exhibit 41: Eisai: YoY revenue growth of Pariet 2011-2014 ($ billions)
Exhibit 42: Eisai: Key takeaways
Exhibit 43: GSK: Business segmentation by revenue 2014
Exhibit 44: GSK: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 45: GSK: Geographical segmentation by revenue 2014
Exhibit 46: GSK: Key takeaways
Exhibit 47: Johnson & Johnson: Business segmentation by revenue 2014
Exhibit 48: Johnson & Johnson: Business segmentation 2013 and 2014 by revenue ($ billions)
Exhibit 49: Johnson & Johnson: Geographical segmentation by revenue 2014
Exhibit 50: Johnson & Johnson: Key takeaways
Exhibit 51: Takeda: Business segmentation by revenue 2014
Exhibit 52: Takeda: Business segmentation by revenue 2013 and 2014 ($ millions)
Exhibit 53: Takeda: Geographical segmentation by revenue 2014
Exhibit 54: Takeda: YoY revenue growth of Prevacid 2012-2014 ($ billions)
Exhibit 55: Takeda: YoY revenue growth of Dexilant 2012-2014 ($ billions)
Exhibit 56: Takeda: YoY revenue growth of Protonix 2012-2014 ($ billions)
Exhibit 57: Takeda: Key takeaways
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Ahn-Gook Pharmaceutical
  • Cancer Advances
  • Daewoong Pharmaceutical
  • GlaxoSmithKline
  • Johnson & Johnson
  • SFJ Pharmaceuticals Group
  • MORE
New Report Released: – Global GERD Market 2016-2020

The author of the report recognizes the following companies as the key players in the Global GERD Market: AstraZeneca, Eisai, GlaxoSmithKline, Johnson & Johnson and Takeda.

Other Prominent Vendors in the market are: Ahn-Gook Pharmaceutical, Cancer Advances, CJ Cheil Jedang, Daewoong Pharmaceutical, Ironwood Pharmaceuticals, RaQualia Pharma, SFJ Pharmaceuticals Group, Sucampo Pharmaceuticals, Vecta Pharmaceuticals, Wockhardt, Yuhan, and Zeria Pharmaceuticals.

Commenting on the report, an analyst from the research team said: “Awareness among individuals about GERD is increasing, and there are various therapies available for its treatment. This would increase the number of treatment-seeking patients, thus giving rise to the overall consumption of related drugs. Similarly, strategic alliances among vendors to consolidate their positions in the market are also expected to exert a positive influence on the market during the forecast period.”

According to the report, the global GERD drugs market is driven the presence of huge unmet medical need in GERD. The lack of FDA approved drugs and the usage of generics and off-label drugs are causing market share erosion of prescription products. Thus, for drug makers, this presents an opportunity to develop therapies that can give them an edge over others to grab a major share of the total GERD drugs market.

Further, the report states that the use of complementary and alternative treatments by patients is a major challenge for the global GERD drugs market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
- AstraZeneca
- Eisai
- GlaxoSmithKline
- Johnson & Johnson
- Takeda
- Ahn-Gook Pharmaceutical
- Cancer Advances
- CJ Cheil Jedang
- Daewoong Pharmaceutical
- Ironwood Pharmaceuticals
- RaQualia Pharma
- SFJ Pharmaceuticals Group
- Sucampo Pharmaceuticals
- Vecta Pharmaceuticals
- Wockhardt
- Yuhan
- Zeria Pharmaceuticals.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll